ATE172719T1 - 1-arylcycloalkyl sulfide, sulfoxide und sulfone zur behandlung von depression, angst und morbus parkinson - Google Patents
1-arylcycloalkyl sulfide, sulfoxide und sulfone zur behandlung von depression, angst und morbus parkinsonInfo
- Publication number
- ATE172719T1 ATE172719T1 AT94916944T AT94916944T ATE172719T1 AT E172719 T1 ATE172719 T1 AT E172719T1 AT 94916944 T AT94916944 T AT 94916944T AT 94916944 T AT94916944 T AT 94916944T AT E172719 T1 ATE172719 T1 AT E172719T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- optionally substituted
- anxiety
- parkinson
- depression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939309749A GB9309749D0 (en) | 1993-05-12 | 1993-05-12 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE172719T1 true ATE172719T1 (de) | 1998-11-15 |
Family
ID=10735317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94916944T ATE172719T1 (de) | 1993-05-12 | 1994-05-07 | 1-arylcycloalkyl sulfide, sulfoxide und sulfone zur behandlung von depression, angst und morbus parkinson |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US5652271A (OSRAM) |
| EP (1) | EP0715620B1 (OSRAM) |
| JP (2) | JP3606326B2 (OSRAM) |
| KR (1) | KR100295264B1 (OSRAM) |
| AT (1) | ATE172719T1 (OSRAM) |
| AU (1) | AU681669B2 (OSRAM) |
| BG (1) | BG61913B1 (OSRAM) |
| BR (2) | BR9406577A (OSRAM) |
| CZ (1) | CZ290711B6 (OSRAM) |
| DE (1) | DE69414264T2 (OSRAM) |
| DK (1) | DK0715620T3 (OSRAM) |
| ES (1) | ES2124411T3 (OSRAM) |
| FI (1) | FI955429L (OSRAM) |
| GB (1) | GB9309749D0 (OSRAM) |
| HU (1) | HU211124A9 (OSRAM) |
| IL (1) | IL109635A (OSRAM) |
| LV (1) | LV11320A (OSRAM) |
| MY (1) | MY110773A (OSRAM) |
| NO (1) | NO305165B1 (OSRAM) |
| NZ (1) | NZ266776A (OSRAM) |
| PH (1) | PH30418A (OSRAM) |
| PL (1) | PL176400B1 (OSRAM) |
| RO (1) | RO115519B1 (OSRAM) |
| RU (1) | RU2135467C1 (OSRAM) |
| SK (1) | SK281257B6 (OSRAM) |
| TW (1) | TW318833B (OSRAM) |
| UA (1) | UA42722C2 (OSRAM) |
| WO (1) | WO1994026704A1 (OSRAM) |
| ZA (1) | ZA943241B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19518988A1 (de) * | 1995-05-29 | 1996-12-05 | Basf Ag | Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit |
| GB9524681D0 (en) | 1995-12-02 | 1996-01-31 | Knoll Ag | Chemical process |
| GB9915617D0 (en) * | 1999-07-05 | 1999-09-01 | Knoll Ag | Therapeutic agents |
| US20060013875A1 (en) * | 2002-05-29 | 2006-01-19 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| US20030224045A1 (en) * | 2002-05-29 | 2003-12-04 | Chien-Hsuan Han | Combination immediate release sustained release levodopa/carbidopa dosage forms |
| US7094427B2 (en) * | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| US20040166159A1 (en) * | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
| WO2007125913A1 (ja) * | 2006-04-26 | 2007-11-08 | Toyama Chemical Co., Ltd. | アルキルエーテル誘導体またはその塩を含有する神経細胞新生誘導剤および精神障害治療剤 |
| MX369315B (es) | 2013-10-07 | 2019-11-05 | Impax Laboratories Inc | Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos. |
| US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| US12194150B2 (en) | 2020-12-22 | 2025-01-14 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52768B1 (en) * | 1981-04-06 | 1988-02-17 | Boots Co Ltd | 1-arylcyclobutylalkylamine compounds useful as therapeutic agents |
| IE56001B1 (en) * | 1982-09-30 | 1991-03-13 | Boots Co Plc | 1-arylcyclobutylmethylamine compounds |
| IE56000B1 (en) * | 1982-09-30 | 1991-03-13 | Boots Co Plc | 1-arylcyclobutylalkylamine compounds |
| GB8501192D0 (en) * | 1985-01-17 | 1985-02-20 | Boots Co Plc | Therapeutic agents |
| CH664957A5 (de) * | 1985-09-24 | 1988-04-15 | Lonza Ag | Verfahren zur herstellung von 4-hydroxy-2-oxo-pyrrolidin-1-yl-acetamid. |
| GB8704777D0 (en) * | 1987-02-28 | 1987-04-01 | Boots Co Plc | Medical treatment |
-
1993
- 1993-05-12 GB GB939309749A patent/GB9309749D0/en active Pending
-
1994
- 1994-05-07 UA UA95114926A patent/UA42722C2/uk unknown
- 1994-05-07 DE DE69414264T patent/DE69414264T2/de not_active Expired - Lifetime
- 1994-05-07 AT AT94916944T patent/ATE172719T1/de active
- 1994-05-07 WO PCT/EP1994/001494 patent/WO1994026704A1/en not_active Ceased
- 1994-05-07 PL PL94311628A patent/PL176400B1/pl unknown
- 1994-05-07 EP EP94916944A patent/EP0715620B1/en not_active Expired - Lifetime
- 1994-05-07 BR BR9406577A patent/BR9406577A/pt not_active Application Discontinuation
- 1994-05-07 DK DK94916944T patent/DK0715620T3/da active
- 1994-05-07 CZ CZ19952936A patent/CZ290711B6/cs not_active IP Right Cessation
- 1994-05-07 JP JP52494694A patent/JP3606326B2/ja not_active Expired - Lifetime
- 1994-05-07 RO RO95-01958A patent/RO115519B1/ro unknown
- 1994-05-07 FI FI955429A patent/FI955429L/fi unknown
- 1994-05-07 AU AU68433/94A patent/AU681669B2/en not_active Expired
- 1994-05-07 SK SK1407-95A patent/SK281257B6/sk not_active IP Right Cessation
- 1994-05-07 RU RU95122740A patent/RU2135467C1/ru active
- 1994-05-07 ES ES94916944T patent/ES2124411T3/es not_active Expired - Lifetime
- 1994-05-07 NZ NZ266776A patent/NZ266776A/en not_active IP Right Cessation
- 1994-05-07 KR KR1019950705037A patent/KR100295264B1/ko not_active Expired - Lifetime
- 1994-05-07 US US08/545,752 patent/US5652271A/en not_active Expired - Lifetime
- 1994-05-11 ZA ZA943241A patent/ZA943241B/xx unknown
- 1994-05-12 IL IL109635A patent/IL109635A/en not_active IP Right Cessation
- 1994-05-12 PH PH48262A patent/PH30418A/en unknown
- 1994-05-12 MY MYPI94001186A patent/MY110773A/en unknown
- 1994-11-11 TW TW083110470A patent/TW318833B/zh active
-
1995
- 1995-06-30 HU HU95P/P00686P patent/HU211124A9/hu unknown
- 1995-11-10 NO NO954542A patent/NO305165B1/no not_active IP Right Cessation
- 1995-11-10 BG BG100127A patent/BG61913B1/bg unknown
- 1995-12-11 LV LV950366A patent/LV11320A/xx unknown
-
1997
- 1997-04-22 BR BR1100306-5A patent/BR1100306A/pt active IP Right Grant
-
2004
- 2004-06-16 JP JP2004178477A patent/JP2004331669A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2146365T3 (es) | Nuevas aril-(alquil)-propil-amidas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen. | |
| ATE172719T1 (de) | 1-arylcycloalkyl sulfide, sulfoxide und sulfone zur behandlung von depression, angst und morbus parkinson | |
| GB9705428D0 (en) | Therapeutic agents | |
| DK0667866T3 (da) | 1,4-benzothiazepiner anvendelige som neurologiske midler | |
| NO961435L (no) | Terapeutiske midler | |
| KR940005534A (ko) | 아릴글리신아미드 유도체, 이의 제조방법 및 활성성분으로서 이를 함유하는 배뇨 장해 치료제 | |
| CA2162706A1 (en) | 1-arylcycloalkyl sulphides, sulphoxides and sulphones for the treatment of depression, anxiety and parkinson's disease | |
| ATE270295T1 (de) | Benzoxazine zur verwendung in der behandlung parkinsonscher krankheit | |
| JO1809B1 (en) | Therapeutic agents | |
| ATE264840T1 (de) | Azetidincarboxamid-derivate zur behandlung von zns störungen | |
| ES2149216T3 (es) | Utilizacion de derivados de piperazina para el tratamiento de trastornos cognoscitivos. | |
| PT1049670E (pt) | Derivados de azetidinocarboxamida para o tratamento de perturbacoes do snc | |
| ATE149352T1 (de) | Thiadiazol-derivate zur behandlung von depressiven zuständen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |